Fulminant hepatic failure necessitating transplantation following the initiation of infliximab therapy: A cautionary tale times two

Transplant International

Volumn 26, Issue 12, 2013, Pages

  Rowe, Bradley W ^a   Gala Lopez, Boris ^a   Tomlinson, Corey ^a   Girgis, Safwat ^a   Shapiro, James A M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; FRESH FROZEN PLASMA; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CHOLESTASIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; ECHOGRAPHY; END STAGE LIVER DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FULMINANT HEPATIC FAILURE; HEPATIC ENCEPHALOPATHY; HOSPITAL DISCHARGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LENGTH OF STAY; LETTER; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER PARENCHYMA; LIVER TRANSPLANTATION; LUPUS VULGARIS; PRIORITY JOURNAL; SPLENOMEGALY; SUPPURATIVE HIDRADENITIS;

ADULT; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; HIDRADENITIS; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MIDDLE AGED;

EID: 84888048522     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12185     Document Type: Letter

References (14)

1. Aringer M, Houssiau F, Gordon C, et al,. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48: 1451.
2. Behm BW, Bickston SJ,. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;(1): CD006893. doi: 10.1002/14651858.CD006893.
3. Carlsen KM, Riis L, Madsen OR,. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009; 28: 1001.
4. Ierardi E, Valle ND, Nacchiero MC, De Francesco V, Stoppino G, Panella C,. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig 2006; 26: 673.
5. Moum B, Konopski Z, Tufteland KF, Jahnsen J,. Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab. Inflamm Bowel Dis 2007; 13: 1584.
6. Sokolove J, Strand V, Greenberg JD, et al,. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1612.
7. Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM,. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26: 578.
8. Menghini VV, Arora AS,. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001; 76: 84.
9. Singh JA, Wells GA, Christensen R, et al,. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;(2): CD008794. doi: 10.1002/14651858.CD008794.pub2.
10. Davern TJ,. Hepatotoxicity of immunomodulating agents and the transplant situation. In:, Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. New York: Informa Healthcare USA, 2007: 663-81.
11. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L,. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010; 5: 193.
12. Subramaniam K, Chitturi S, Brown M, Pavli P,. Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate. Inflamm Bowel Dis 2011; 17: E149.
13. van Casteren-Messidoro C, Prins G, van Tilburg A, Zelinkova Z, Schouten J, de Man R,. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis 2012; 6: 630.
14. Aithal GP,. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011; 7: 139.